Introduction The understanding of obesity has changed since 2003, and in 2013, the American Medical Association officially recognized it as a disease.1 The treatment landscape for obesity has also undergone a considerable transformation with the development of highly effective glucagon-like peptide-1 receptor agonists (GLP-1RAs). This new class of antiobesity medications (AOMs) offers substantial clinical benefits, such as sizable weight loss and reductions in obesity-related comorbidities.